DelMar to acquire Adgero Biopharmaceuticals in all-equity transaction
By Nikita Chaurasia  Date: 2020-06-11

DelMar to acquire Adgero Biopharmaceuticals in all-equity transaction

DelMar Pharmaceuticals, Inc., the American-based biopharmaceutical company focused on the development of novel cancer therapies, has reportedly inked agreement to acquire Adgero Biopharmaceuticals Holdings, Inc. in an all-equity transaction.

Sources cite that Adgero stockholders will get shares of DelMar common stock for shares of Adgero common stock. Following the completion of the deal, the stockholders of DelMar and Adgero will own 50.5 percent and 49.5 percent of the total voting power of the joint company respectively.

Expected to close in the Q3 2020, the deal is subject to stockholder approval of two companies and other closing conditions. Kintara Therapeutics, Inc. will be a new name for the combined company and expected to trade on NASDAQ under new symbol ‘KTRA’

The merger will create a diversified biopharmaceutical company with a vigorous product pipeline targeting unmet medical needs in oncology. The joint company will work on two late-stage, Phase 3-ready cancer treatments – VAL for GBM (glioblastoma multiforme) and REM-001 for CMB (cutaneous metastatic breast cancer). Moreover, the combined company will work on several last-state clinical research over the next 12-18 months.

For the record, Adgero is a biopharmaceutical company focused on developing its late-stage photodynamic therapy platform for treating serious cutaneous oncology indications. The joint company will bring together DelMar's DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's last stage photodynamic therapy platform. 

Speaking on which, Saiid Zarrabian, Chief Executive Officer and President of DelMar said that this merger is the result of a widespread search for suitable oncology therapy and offers the combined company with a diversified last-stage oncology pipeline.

John Liatos, Chief Financial Officer and interim Chief Executive Officer of Adgero said that with this deal, the company is looking forward to developing a highly focused oncology company that can develop novel therapies to support patients and physicians where existing treatment options are limited.

Source Credit -https://www.delmarpharma.com/news-media/press-releases/detail/933/delmar-to-acquire-adgero-biopharmaceuticals-expand

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Generac, Baker partner to offer solar & storage installations in U.S.
Generac, Baker partner to offer solar & storage installations in U.S.
By Nikita Chaurasia

Generac Holdings Inc., a Wisconsin-based leading backup power generation developer, has reportedly entered a joint venture agreement with a solar electric solutions provider Baker Electric Home Energy. Sources close to the matter stated that the two ...

Education analytics platform HelioCampus acquires ABC Insights
Education analytics platform HelioCampus acquires ABC Insights
By Nikita Chaurasia

HelioCampus, a leading higher education analytics platform that offers universities and colleges the decision-support assistance they require to work more sustainably and strategically, has reportedly announced that it acquired ABC Insights, a renown...

Deutsche Telekom, OVHcloud partner to offer cloud services in Europe
Deutsche Telekom, OVHcloud partner to offer cloud services in Europe
By Nikita Chaurasia

Deutsche Telekom AG, the German telecommunication services provider, has reportedly teamed up with a France-based company OVHcloud. Sources with knowledge of the matter stated that the two companies intend to provide alternative cloud computing servi...

Graphics firm NVIDIA to acquire Arm from SoftBank for $40 billion
Graphics firm NVIDIA to acquire Arm from SoftBank for $40 billion
By Nikita Chaurasia

NVIDIA, a leading American multinational technology firm, and SoftBank, a renowned Japanese conglomerate, have reportedly announced that NVIDIA would acquire Arm Limited from SoftBank Group for a total amount of $40 billion. The agreement would be im...

QHR Health buys Resolution to reinforce its community health services
QHR Health buys Resolution to reinforce its community health services
By Nikita Chaurasia

In a recent turn of events, U.S.-based technological healthcare company QHR Health has reportedly announced the acquisition of revenue cycle services provider, Resolution, in order to strengthen its community healthcare services across the United Sta...